CMS allows coverage of genomic testing to go beyond advanced cancer diagnoses

Why This Topic Matters

Coverage policy changes for NGS can affect whether genomic tests are payable under Medicare and how providers prepare documentation, ordering, and billing workflows. Understanding the scope of national and local coverage guidance helps organizations track access to molecular testing and anticipate changes in diagnostic lab reimbursement.

Article Sections

1. CMS coverage update for next generation sequencing

   Introduces the Medicare policy update and the broader context for genomic testing coverage under CMS review.

2. Expanded diagnostic testing discretion for MACs

   Summarizes the role of regional Medicare administrative contractors and the types of non-cancer testing they may consider under local coverage policies.

3. NGS expansion a ‘positive step’

   Provides background on next generation sequencing, its clinical and research uses, and comments from industry and professional organizations.

4. Wrap in the fine print

   Outlines the general coverage conditions CMS associates with diagnostic laboratory testing using NGS and notes implementation considerations.